Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

Luciana Armaganijan, Karen Alexander, Zhen Huang, Pierluigi Tricoci, Claes Held, Frans Van de Werf, Paul Armstrong, Philip Aylward, Harvey White, David Moliterno, Lars Wallentin, Edmond Chen, Robert Harrington, John Strony, Kenneth Mahaffey, Renato Lopes

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science